Related Experiment Video
Updated: Feb 27, 2026
Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
Published on: April 5, 2019
Development and Validation of a Functional Antibody Assay for Evaluating Protein-Based Pneumococcal Vaccines
Jiangjiao Li1, Kang Li1, Youyou Wang1
1State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 102629, China.
Insights
A new functional antibody assay was developed for pneumococcal surface protein A (PspA) vaccines. This assay supports the development of novel protein-based vaccines against Streptococcus pneumoniae infections.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Streptococcus pneumoniae (Spn) causes severe invasive diseases like meningitis and pneumonia.
- Current polysaccharide vaccines have limitations including serotype replacement.
- Pneumococcal surface protein A (PspA) is a promising antigen for new protein-based vaccines.
Purpose of the Study:
- To establish a standardized functional antibody assay for PspA-based vaccines.
- To overcome limitations in current antibody detection methods for pneumococcal vaccines.
Main Methods:
- Modified the multiplex opsonophagocytic killing assay (MOPA) for PspA.
- Selected and developed a target strain panel using PCR and ELISA.
- Optimized MOPA by extending phagocytic reaction time and confirmed specificity via competitive inhibition assays.
Main Results:
- The assay showed high linearity (R² ≥ 0.98) and acceptable precision (CV ≤ 30% repeatability, CV ≤ 50% intermediate precision).
- Preclinical and clinical serum samples demonstrated potent bactericidal activity against diverse PspA families, irrespective of capsule type.
Conclusions:
- A standardized framework was provided for developing and assessing protein-based pneumococcal vaccines.
- The assay facilitates the evaluation of functional antibodies against PspA, crucial for vaccine efficacy.
Background:
Streptococcus pneumoniae (Spn) is a leading bacterial pathogen responsible for severe invasive diseases, including meningitis, sepsis, and pneumonia. Current pneumococcal vaccines, which are all based on capsular polysaccharide antigens, provide limited protection and are further compromised by post-vaccination serotype replacement. Pneumococcal surface protein A (PspA), a highly conserved virulence factor expressed across diverse serotypes, has emerged as a promising candidate antigen for novel protein-based vaccines. However, progress in this field has been hindered by the absence of standardized in vitro functional antibody assays.
Methods:
This study established a robust functional antibody detection method for PspA-based protein vaccines by modifying the conventional multiplex opsonophagocytic killing assay (MOPA), originally designed for polysaccharide-based vaccines. Using polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) typing, a target strain panel was selected and developed to include representative strains from PspA Family 1-Clade 2 and Family 2-Clades 3 and 4. The MOPA protocol was optimized by extending the phagocytic reaction time to enhance sensitivity. Specificity was confirmed through recombinant PspA competitive inhibition assays.
Results:
The assay demonstrated high linearity (R2 ≥ 0.98) between opsonophagocytic index (OI) and serum dilution, along with acceptable repeatability (CV ≤ 30%) and intermediate precision (CV ≤ 50%). Both preclinical and clinical serum samples exhibited potent bactericidal activity against diverse PspA families, independent of capsule type.
Conclusions:
This study provided a standardized framework to support the development and regulatory assessment of protein-based pneumococcal vaccines.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
06:04Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
